MAN1B1-CDG (also called Rafiq syndrome) is an autosomal-recessive congenital disorder of glycosylation type II caused by loss of MAN1B1, a class I alpha-1,2-mannosidase that initiates trimming of Man9GlcNAc2 precursors and participates in glycoprotein quality control. Patients show intellectual disability, developmental delay, dysmorphism and variable obesity. The source study (Van Scherpenzeel et al., Brain, 2014) established a rapid mass-spectrometric glycoprofile of intact plasma transferrin — accumulation of hybrid-type N-glycans — as a diagnostic signature. Its results, together with those of the companion paper (Rymen et al., PLoS Genetics 2013), leave four linked questions unresolved: which brain glycoproteins carry the aberrant hybrid-type N-glycans and which abnormal glycosylation events are causally linked to impaired neurodevelopment; how MAN1B1 loss mechanistically connects to the observed Golgi fragmentation and to perturbation of endoplasmic-reticulum-associated degradation (ERAD); how substrate-specific hybrid-glycan accumulation varies across glycoproteins in vivo and maps onto the marked phenotypic heterogeneity among patients; and the diagnostic boundaries — sensitivity, specificity and false-negative rate — of the intact-transferrin assay in broader patient populations. What remains unresolved is the mechanistic core — brain glycoprotein targets, CNS vulnerability and Golgi/ERAD pathophysiology in patients — together with validation of the diagnostic performance of the intact-transferrin assay.

Background

N-linked protein glycosylation is the covalent attachment of oligosaccharides (N-glycans) to asparagine residues, beginning in the endoplasmic reticulum (ER) with transfer of a lipid-linked precursor glycan and continuing with stepwise enzymatic trimming and rebuilding in the ER and Golgi apparatus. Congenital disorders of glycosylation (CDG) are inherited defects of this pathway; they are grouped into type I (cytosol/ER assembly and transfer steps) and type II (Golgi processing and trimming). CDG type II subtypes have been comparatively hard to unravel because classic serum screening — isoelectric focusing of transferrin, which reports the number of loaded glycosylation sites and glycan charge — lacks structural specificity for many processing defects. High-resolution mass spectrometry of intact transferrin, which resolves individual glycoforms and hence glycan structures, was introduced to close this gap. MAN1B1 encodes a class I alpha-1,2-mannosidase (historically called ER mannosidase I, ERManI) that removes one terminal mannose from the middle branch of Man9GlcNAc2, generating Man8GlcNAc2 isomer B, an early step that enables later hybrid and complex N-glycan maturation. Hybrid-type N-glycans are structures in which one branch has been fully processed (with galactose, sialic acid, etc.) while the other retains untrimmed mannose residues — the signature structures that accumulate when MAN1B1 activity is deficient. MAN1B1 was also the first mannosidase implicated in ER-associated degradation (ERAD), the quality-control pathway that retrotranslocates misfolded proteins to the cytosol for proteasomal destruction: mannose trimming is thought to act as a molecular clock marking persistently misfolded glycoproteins for disposal. Unexpectedly, the endogenous MAN1B1 protein resides mainly in the Golgi, where it acts as a non-enzymatic gatekeeper that retrieves escaped ERAD substrates through interaction with the COPI retrograde-trafficking machinery (Pan et al. 2013; Iannotti et al. 2014). MAN1B1 was first linked to disease by Rafiq et al. (2011), who identified recessive MAN1B1 mutations in families with non-syndromic autosomal-recessive intellectual disability. Rymen et al. (2013) then reclassified the defect as a frequent CDG type II (over 25% of the unsolved CDG-II cases in their cohort): patient fibroblasts showed delayed Man9-to-Man8 trimming, only faint Golgi MAN1B1 signal, and altered Golgi morphology with dilated, fragmented cisternae — observations that raised competing mechanistic hypotheses (Golgi 'storage' of retained glycoproteins versus increased secretion of misfolded glycoproteins) and left the pathophysiology explicitly unresolved. The source study, Van Scherpenzeel et al. (2014), analyzed a series of 12 MAN1B1-deficient patients: high-resolution glycoprofiling of intact plasma transferrin revealed a highly characteristic hybrid-type N-glycan signature; abnormal hybrid glycans also appeared, in variable amounts, on total serum proteins, enriched immunoglobulins and alpha1-antitrypsin; clinically the group had intellectual disability, delayed motor and speech development, dysmorphism and truncal obesity or macrocephaly in roughly 65%. The authors proposed the intact-transferrin assay as a rapid screen for MAN1B1 deficiency within CDG-II cohorts and in intellectual-disability cohorts. What remains open after these studies — and what a decade of follow-up literature has still not settled — is how this glycosylation defect actually produces neurological disease: the identity of the brain glycoproteins that carry the aberrant hybrid-type N-glycans, the causal chain from MAN1B1 loss through Golgi disruption and ERAD perturbation to impaired neurodevelopment, the relationship between substrate-specific glycan accumulation and the heterogeneous patient phenotypes, and the real-world diagnostic performance (sensitivity, specificity, false-negative rate) of the serum assay across diverse populations.

Problem Statement

Determine how MAN1B1 deficiency produces neurodevelopmental disease and how reliably it can be detected in the clinic. Specifically: (1) identify which glycoproteins in the central nervous system carry the aberrant hybrid-type N-glycans that characterize MAN1B1-CDG, and establish which of those abnormal glycosylation events are causally linked to impaired neurodevelopment; (2) clarify experimentally, in appropriate model systems, the mechanistic connection between loss of MAN1B1, the accumulation of hybrid and high-mannose N-glycans, the alterations of Golgi morphology (dilatation and fragmentation of cisternae) observed in patient cells, and the perturbation of glycoprotein quality control (endoplasmic-reticulum-associated degradation and related disposal routes); (3) determine, through broader in-vivo glycoproteomic studies, how hybrid-type glycan accumulation varies across different glycoprotein substrates and how this substrate-specific variability contributes to the phenotypic heterogeneity observed among patients; and (4) establish the diagnostic boundaries of the intact-transferrin mass-spectrometry glycoprofile — its sensitivity and specificity across diverse patient populations, including its false-negative behavior when hybrid glycans are present at low abundance on transferrin but enriched on other serum proteins. These four questions are all mandatory parts of one objective, an integrated pathomechanistic and diagnostically validated account of MAN1B1-CDG, in which the mechanistic facets (1)-(3) are tied to the recognized clinical phenotype and facet (4) is established with quantitative sensitivity, specificity and false-negative estimates.

References

  1. Van Scherpenzeel M, Timal S, Rymen D, Hoischen A, Wuhrer M, Hipgrave-Ederveen A, Grunewald S, Peanne R, Saada A, Edvardson S, Grønborg S, Ruijter G, Kattentidt-Mouravieva A, Brum JM, Freckmann ML, Tomkins S, Jalan A, Prochazkova D, Ondruskova N, Hansikova H, Willemsen MA, Hensbergen PJ, Matthijs G, Wevers RA, Veltman JA, Morava E, Lefeber DJ. Diagnostic serum glycosylation profile in patients with intellectual disability as a result of MAN1B1 deficiency. Brain 137(Pt 4):1030-1038 (2014). DOI 10.1093/brain/awu019. https://doi.org/10.1093/brain/awu019
  2. Rymen D, Peanne R, Millón MB, Race V, Sturiale L, Garozzo D, Mills P, Clayton P, Asteggiano CG, Quelhas D, Cansu A, Martins E, Nassogne MC, Gonçalves-Rocha M, Topaloglu H, Jaeken J, Foulquier F, Matthijs G. MAN1B1 deficiency: an unexpected CDG-II. PLoS Genetics 9(12):e1003989 (2013). DOI 10.1371/journal.pgen.1003989. https://doi.org/10.1371/journal.pgen.1003989
  3. Rafiq MA, Kuss AW, Puettmann L, Noor A, Ramiah A, Ali G, Hu H, Kerio NA, Xiang Y, Garshasbi M, Khan MA, Ishak GE, Weksberg R, Ullmann R, Tzschach A, Kahrizi K, Mahmood K, Naeem F, Ayub M, Moremen KW, Vincent JB, Ropers HH, Ansar M, Najmabadi H. Mutations in the alpha 1,2-mannosidase gene, MAN1B1, cause autosomal-recessive intellectual disability. American Journal of Human Genetics 89(1):176-182 (2011). DOI 10.1016/j.ajhg.2011.06.006. https://doi.org/10.1016/j.ajhg.2011.06.006
  4. Pan S, Cheng X, Sifers RN. Golgi-situated endoplasmic reticulum alpha-1,2-mannosidase contributes to the retrieval of ERAD substrates through a direct interaction with gamma-COP. Molecular Biology of the Cell 24(8):1111-1121 (2013). DOI 10.1091/mbc.E12-12-0886. https://doi.org/10.1091/mbc.E12-12-0886
  5. Iannotti MJ, Figard L, Sokac AM, Sifers RN. A Golgi-localized mannosidase (MAN1B1) plays a non-enzymatic gatekeeper role in protein biosynthetic quality control. Journal of Biological Chemistry 289(17):11844-11858 (2014). DOI 10.1074/jbc.M114.552091. https://doi.org/10.1074/jbc.M114.552091
  6. van Scherpenzeel M, Steenbergen G, Morava E, Wevers RA, Lefeber DJ. High-resolution mass spectrometry glycoprofiling of intact transferrin for diagnosis and subtype identification in the congenital disorders of glycosylation. Translational Research 166(6):639-649.e1 (2015). DOI 10.1016/j.trsl.2015.07.005. https://doi.org/10.1016/j.trsl.2015.07.005
  7. Saldova R, Stöckmann H, O'Flaherty R, Lefeber DJ, Jaeken J, Rudd PM. N-Glycosylation of Serum IgG and Total Glycoproteins in MAN1B1 Deficiency. Journal of Proteome Research 14(10):4402-4412 (2015). DOI 10.1021/acs.jproteome.5b00709. https://doi.org/10.1021/acs.jproteome.5b00709
  8. Duvet S, Mouajjah D, Péanne R, Matthijs G, Raymond K, Jaeken J, Morava E, Foulquier F. Use of Endoglycosidase H as a diagnostic tool for MAN1B1-CDG patients. Electrophoresis 39(24):3133-3141 (2018). DOI 10.1002/elps.201800020. https://doi.org/10.1002/elps.201800020
  9. Balasubramanian M, Johnson DS; DDD Study. MAN1B-CDG: Novel variants with a distinct phenotype and review of literature. European Journal of Medical Genetics 62(2):109-114 (2019). DOI 10.1016/j.ejmg.2018.06.011. https://doi.org/10.1016/j.ejmg.2018.06.011
  10. Sun AH, Collette JR, Sifers RN. The cytoplasmic tail of human mannosidase Man1b1 contributes to catalysis-independent quality control of misfolded alpha1-antitrypsin. Proceedings of the National Academy of Sciences USA 117(40):24825-24836 (2020). DOI 10.1073/pnas.1919013117. https://doi.org/10.1073/pnas.1919013117
  11. Okamoto N, Ohto T, Enokizono T, Wada Y, Kohmoto T, Imoto I, Haga Y, Seino J, Suzuki T. Siblings with MAN1B1-CDG Showing Novel Biochemical Profiles. Cells 10(11):3117 (2021). DOI 10.3390/cells10113117. https://doi.org/10.3390/cells10113117
  12. Sakhi S, Cholet S, Wehbi S, Isidor B, Cogne B, Vuillaumier-Barrot S, Dupré T, Detleft T, Schmitt E, Leheup B, Bonnet C, Feillet F, Muti C, Fenaille F, Bruneel A. MAN1B1-CDG: Three new individuals and associated biochemical profiles. Molecular Genetics and Metabolism Reports 28:100775 (2021). DOI 10.1016/j.ymgmr.2021.100775. https://doi.org/10.1016/j.ymgmr.2021.100775
  13. Kemme L, Grüneberg M, Reunert J, Rust S, Park J, Westermann C, Wada Y, Schwartz O, Marquardt T. Translational balancing questioned: Unaltered glycosylation during disulfiram treatment in mannosyl-oligosaccharide alpha-1,2-mannnosidase-congenital disorders of glycosylation (MAN1B1-CDG). JIMD Reports 60(1):42-55 (2021). DOI 10.1002/jmd2.12213. https://doi.org/10.1002/jmd2.12213
  14. Noel M, Zürcher YM, Tulin EKC, Cummings RD. The Importance of N- and O-Glycosylation of Brain Cell Surface Glycoproteins. Glycobiology 35(11):cwaf054 (2025). DOI 10.1093/glycob/cwaf054. https://doi.org/10.1093/glycob/cwaf054
  15. Iskafi R, AbuRahmeh B, Aljuneidi R, AlShweiki H, Abdelnabi S, Abukhalaf A, Maraqa B. A Case of Rafiq Syndrome (MAN1B1-CDG) in a Palestinian Child, With Brief Literature Review of 44 Cases. Journal of Investigative Medicine High Impact Case Reports 13:23247096251313731 (2025). DOI 10.1177/23247096251313731. https://doi.org/10.1177/23247096251313731
  16. Zhang J, Lu X, Li S, Wang T, Ahmad I, Zheng YH. Membralin Assembles a MAN1B1-VCP Complex to Target Foreign Glycoproteins from the Endoplasmic Reticulum to Lysosomes for Degradation. Advanced Science 13(9):e19256 (2026). DOI 10.1002/advs.202519256. https://doi.org/10.1002/advs.202519256
  17. Mól AR, Fontes NDC, Santos SCL, Costa E Silva C, Carvalho GHS, Lima BJCB, de Mello WD, de Carvalho DR, Barbosa EA, Lefeber DJ, Mazzeu JF, Brum JM, Brand GD. Diagnosis of Congenital Disorders of Glycosylation Type II Subtypes Through Comprehensive N-Glycan Profiling by Mass Spectrometry. International Journal of Molecular Sciences 27(14):6309 (2026). DOI 10.3390/ijms27146309. https://doi.org/10.3390/ijms27146309
  18. Neves CJ, Gomes A, Lourenço RA, Barbosa M, Grosso AR, Videira PA. Tissue-specific expression and regulation of congenital disorders of glycosylation genes: A GTEx-based in silico study. Molecular Genetics and Metabolism Reports 48:101336 (2026). DOI 10.1016/j.ymgmr.2026.101336. https://doi.org/10.1016/j.ymgmr.2026.101336
  19. Schultz MJ, Liedtke KL, Turgeon CT, Matern D, Hall PL. Biochemical genetic testing for congenital disorders of glycosylation after sequencing produces equivocal results. Molecular Genetics and Metabolism 148(2):109910 (2026). DOI 10.1016/j.ymgme.2026.109910. https://doi.org/10.1016/j.ymgme.2026.109910